Table 3. Survival analysis of 158 GC patients with BGS detection of ZNF545 promoter methylation.
| Variables | Median OS (mo) | X2 value | Univariate P value | HR value | Multivariate P value | BIC value |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male | 20 | 0.911 | 0.340 | |||
| Female | 22 | |||||
| Age at surgery (years) | ||||||
| ≤ 60 | 20 | 0.011 | 0.915 | |||
| > 60 | 21 | |||||
| Tumor location | ||||||
| Upper third | 17 | 9.642 | 0.022 | |||
| Middle third | 20 | |||||
| Lower third | 26 | |||||
| ≥ 2/3 stomach | 16 | |||||
| Tumor size (cm) | ||||||
| < 4.0 | 27 | 3.040 | 0.081 | |||
| ≥ 4.0 | 20 | |||||
| Lauren classification | ||||||
| Intestinal | 26 | 3.430 | 0.180 | |||
| Diffuse | 20 | |||||
| Mixed | 17 | |||||
| Depth of tumor invasion (T stage) | ||||||
| T1 | 70 | 20.677 | < 0.001 | 1.659 (1.224–2.249) | 0.001 | 56.968 |
| T2 | 33 | |||||
| T3 | 23 | |||||
| T4 | 12 | |||||
| Number of metastatic lymph nodes (N stage) | ||||||
| N0 | 48 | 43.150 | < 0.001 | 1.659 (1.381–1.993) | < 0.001 | 74.211 |
| N1 | 25 | |||||
| N2 | 18 | |||||
| N3 | 11 | |||||
| Location of lymph node metastasis | ||||||
| No | 48 | 23.436 | < 0.001 | |||
| Perigastric | 17 | |||||
| Extragastric | 18 | |||||
| Methylated CpG site count | ||||||
| 2 or less | 27 | 4.497 | 0.034 | |||
| 3 or more | 19 | |||||
| Methylated status of CpG −232 | ||||||
| Unmethylated | 24 | 4.109 | 0.043 | 1.490 (1.057–2.099) | 0.023 | 68.817 |
| Methylated | 17 | |||||
| Methylated status of CpG −214 | ||||||
| Unmethylated | 26 | 4.353 | 0.037 | |||
| Methylated | 18 | |||||
| Methylated status of CpG −176 | ||||||
| Unmethylated | 26 | 5.250 | 0.022 | |||
| Methylated | 18 | |||||
| Methylated status of CpG −144 | ||||||
| Unmethylated | 26 | 4.321 | 0.038 | |||
| Methylated | 18 | |||||
| Methylated status of CpG −116 | ||||||
| Unmethylated | 24 | 4.884 | 0.027 | |||
| Methylated | 18 | |||||